With the recent rapid advances in the use of immune checkpoint inhibitors to treat cancer, the therapeutic targeting of OPN has particularly come to the fore in view of findings that OPN can bypass anti-PD1 immunotherapy [33,37]. The gene discussed is SPP1; the disease is cancer.